Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - Pharmaceutical News - ITL Pharma Receives United States Patent Protection for TriThroid Using Sustained Drug Release and Improved Product Stability [Tehran Times (Iran)] - November 21, 2017

Pharmacy News Article

 2/15/17 - ITL Pharma Receives United States Patent Protection for TriThroid Using Sustained Drug Release and Improved Product Stability [Tehran Times (Iran)]

(GlobeNewswire) - ITL Pharma, Inc. (ITL), a LIAS Research Company, today announced awarding of a United States Patent (US 9,526,701) titled: "Sustained Drug Release and Improved Product Stability Using Non-Covalent Particle Coating Methods." This "umbrella" patent provides a novel approach to drug delivery, allowing for extended product stability and controlled release of the API.

TriThroid (T3, Liothyronine, Na) is the lead product in the pipeline of products utilizing this technology. TriThroid, now through Phase II clinical trials, provides for once-per-day dosing to fully replace thyroxine (T4) based products and is projected to be especially effective in hypothyroid patients that cannot effectively convert T4 to T3, by providing the active hormone (T3) directly to thyroid hormone target tissues.

"This new Patent is a significant break-through in providing shelf-stable products with sustained drug release and pH dependent PK profiles, said Dr. Keith R. Latham, ITL`s Chief Executive Officer. "This new Patent also provides a critical advance in the delivery of additional drugs in our pipeline including treatments for Cancer, Thyroid, Parkinson`s, Alzheimer`s and Inflammatory Diseases."

About ITL PharmaITL Pharma, Inc. is a privately held US Pharmaceutical company headquartered in Kingsport, Tennessee. Established in VA in 1996 by merger of Inovar Chemicals, Innovative Technologies and Technology Resources, ITL now focuses on new drug discovery and development with 22 new pipeline drugs in 8 therapeutic arenas (

ITL has now completed Phase II clinical trials on TriThroid, a sustained release, sustained effects, once-per-day dosing product containing Liothyronine (T3) as the API. This prescription product will replace Levothyroxine (T4) products in a $3.4 Billion market. ITL`s vertical integration program anticipates Partnering with companies specializing in market launch and World-Wide distribution and sales.

About LIAS ResearchLatham Institute of Advanced Science (LIAS), the parent company for ITL Pharma, provides program integration and management resources to the LIAS Family of Companies. LIAS companies have a pipeline of new prescription drugs and marketed Over the Counter (OTC) products. LIAS CEO, Gina Garland, stated: We are very pleased with the outstanding progress ITL has made in the treatment of hypothyroidism and other diseases.


Dr. Keith R. Latham, CEO

ITL Pharma, Inc.


(c) 2017 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Last Chance
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Nov 29: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement